Cactus Life Sciences
24.4.2024 15:48:41 CEST | ACCESS Newswire | Press release
Cactus Life Sciences has begun their exciting buy-and-build strategy adding key services to their portfolio
PRINCETON, NJ / ACCESSWIRE / April 24, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that they have acquired nspm and eluSCIdate, two dynamic medical communications and publications companies headquartered in Meggen, Switzerland with an office in the UK.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.logo lockup
Cactus Life Sciences, headquartered in Princeton, New Jersey, was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. Founded 27 years ago, nspm brings extensive expertise in medical communications, publications, and event management, with a focus on rare diseases. Its sister company eluSCIdate was founded in 2020 and focuses on medical and scientific publications, combining extensive experience in medical writing with creative flair to deliver high-quality publications.
This collaboration signifies a major step forward in enhancing services for our biopharma clients, ensuring a comprehensive and fully integrated global approach to medical communications. And provides a significant employee footprint in US, UK, Switzerland, and Japan.
"As Cactus Life Sciences embarks on its forthcoming buy-and-build strategy, we're excited to unveil our first acquisition that shares so many of the same values as CACTUS, stated Oliver Dennis, the new Chairman of Cactus Life Sciences. "As we move forward, we seek partnerships that prioritize our people and clients alongside our strategic growth."
Rare diseases individually affect a small number of people, but collectively affect over 300 million worldwide, presenting significant challenges for patients and medical professionals. nspm's rare disease expertise addresses unmet needs for patients and society. Sabine Stotz, PhD, Managing Director, nspm, noted "This strategic alliance is a testament to the shared vision of excellence between Cactus Life Sciences, nspm and eluSCIdate. Together, our goal is to enrich the global landscape of scientific communications creating an even greater impact on healthcare professionals and the patients they treat".
Elvira Dsouza, President, Cactus Life Sciences remarked, "Cactus Life Sciences stands out for its unwavering commitment to excellence, innovation, and future readiness. With a focus on integrating cutting-edge technology, notably AI, we aim to elevate scientific content creation to contribute to a more accessible, informed, and transformative healthcare landscape".
About Cactus Life Sciences (cactuslifesciences.com): Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.
About nspm (www.nspm.com): nspm is a successful and dynamic medical communications company founded in 1997 with offices in Switzerland and the UK. nspm provides a complete range of medical writing, project management, and strategic medical communications solutions for the pharmaceutical and biotech industry across a range of therapeutic areas, with a focus on rare diseases. Our employees are committed to crafting high-quality, cost-effective solutions that exceed clients' expectations through scientific excellence, professionalism, and creativity.
About eluSCIdate (www.eluscidate.com): eluSCIdate is a medical writing agency founded in 2020 that specializes in scientific publications, providing support for the entire publication process. We use a wealth of experience in medical writing to deliver high-quality manuscripts, posters, and slides to our clients. At eluSCIdate, we are passionate about science and committed to providing clarity in scientific messaging. Through effective communication, we work with our clients to ensure their science stands out from the crowd.
Contact Information:
Laura Perry
VP of Strategy and Marketing
inquiries@cactuslifesciences.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom